Q4 Earnings Forecast for SGMO Issued By HC Wainwright

Key Points

• HC Wainwright projects Sangamo Therapeutics' Q4 2026 earnings per share (EPS) at $0.01, while the full-year estimate is currently at ($0.46) per share.
• The company's most recent earnings were disappointing, reporting ($0.08) EPS and missing estimates, with revenues of $18.31 million falling short of the expected $31.68 million.
• Analyst ratings are mixed, with one sell rating, two hold ratings, and four buy ratings, while the average price target has been set around $4.50.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at HC Wainwright issued their Q4 2026 earnings estimates for Sangamo Therapeutics in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2029 earnings at $0.33 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%.

SGMO has been the subject of a number of other research reports. Wall Street Zen raised shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Barclays decreased their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded down $0.0331 during mid-day trading on Thursday, reaching $0.5560. The company's stock had a trading volume of 3,229,543 shares, compared to its average volume of 6,116,046. The company has a market capitalization of $167.75 million, a price-to-earnings ratio of -1.91 and a beta of 1.18. Sangamo Therapeutics has a 12 month low of $0.4111 and a 12 month high of $3.1790. The business's 50 day simple moving average is $0.52 and its 200 day simple moving average is $0.70.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently modified their holdings of the stock. Wasatch Advisors LP raised its position in shares of Sangamo Therapeutics by 17.7% in the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock valued at $4,376,000 after purchasing an additional 1,215,653 shares during the period. Engineers Gate Manager LP raised its position in shares of Sangamo Therapeutics by 101.7% in the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 44,078 shares during the period. Invesco Ltd. raised its position in shares of Sangamo Therapeutics by 40.6% in the second quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company's stock valued at $368,000 after purchasing an additional 196,558 shares during the period. XTX Topco Ltd bought a new position in shares of Sangamo Therapeutics in the second quarter valued at about $41,000. Finally, Geode Capital Management LLC raised its position in shares of Sangamo Therapeutics by 2.1% in the second quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company's stock valued at $1,263,000 after purchasing an additional 48,829 shares during the period. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.